Pertussis Clinical Presentation and Diagnosis

Clinical Features and Phases

• The Centers for Disease Control and Prevention recommends recognizing pertussis through its three distinct phases of illness: catarrhal phase, paroxysmal phase, and convalescent phase, which are characterized by nonspecific symptoms, paroxysmal cough, and gradual improvement, respectively 1, 2
• The catarrhal phase lasts 1-2 weeks and is marked by nonspecific symptoms such as coryza, intermittent cough, sneezing, lacrimation, and minimal fever, making it clinically indistinguishable from minor respiratory infections 1, 2
• The paroxysmal phase, lasting 4-6 weeks, is characterized by paroxysmal cough, posttussive vomiting, and inspiratory whoop, which are the hallmark symptoms of pertussis 3, 1, 2
• The convalescent phase, lasting 2-6 weeks or longer, is marked by gradual improvement with decreasing frequency of coughing bouts, although nonparoxysmal cough can persist for months 1, 2

Diagnostic Considerations

• The American Academy of Pediatrics and the Centers for Disease Control and Prevention suggest that for adults with acute or subacute cough, assessing for paroxysmal cough, posttussive vomiting, inspiratory whooping, and absence of fever can help rule in or out pertussis 3
• Paroxysmal cough has high sensitivity (93.2%) but low specificity (20.6%) for pertussis, meaning its absence makes pertussis unlikely 3
• Posttussive vomiting has low sensitivity but high specificity (77.7%) for pertussis, and when present, strongly suggests the disease 3
• Inspiratory whoop has low sensitivity but high specificity (79.5%) for pertussis, and when present, strongly suggests the disease 3

Special Considerations

• The Centers for Disease Control and Prevention advises against dismissing pertussis in vaccinated adolescents and adults, as the illness can be milder with absent whoop in previously vaccinated individuals 1, 2
• The American Academy of Pediatrics recommends not waiting for laboratory confirmation to initiate treatment, as antibiotics should be started when pertussis is clinically suspected to prevent transmission 1, 2
• Infants with atypical presentation, such as apneic spells and minimal cough, should not be overlooked, as they can be infected with pertussis 2
• Patients are most infectious during the catarrhal stage and first 3 weeks after cough onset, when symptoms are least specific 1, 2

Pertussis Diagnostic Approach and Management

Clinical Assessment

• The American Thoracic Society recommends assessing adults with acute or subacute cough for four key characteristics: paroxysmal cough, posttussive vomiting, inspiratory whooping, and absence of fever, as pertussis is unlikely if the patient has fever or if the cough is not paroxysmal in nature 4, 5
• The presence of posttussive vomiting or inspiratory whooping sound is highly suggestive of pertussis, with high specificity (77.7% and 79.5% respectively) but low sensitivity 6, 7
• Paroxysmal cough has high sensitivity (93.2%) but low specificity (20.6%) for pertussis in adults 7
• For children with acute cough, the American Academy of Pediatrics recommends assessing for the three classical characteristics: paroxysmal cough, posttussive vomiting, and inspiratory whooping, with posttussive vomiting having moderate sensitivity (60.0%) and specificity (66.0%) 8, 5

Laboratory Confirmation

• The Centers for Disease Control and Prevention recommends polymerase chain reaction (PCR) testing of nasopharyngeal specimens as the preferred confirmatory test, although other methods such as culture (100% specific) and serology (72%-100% specific) can also be used 6, 8
• Oral fluid testing has a specificity of 91%-99% for pertussis diagnosis 6

Treatment Approach

• The American Academy of Pediatrics recommends initiating macrolide antibiotics (preferably azithromycin) when pertussis is suspected to prevent transmission, even though it may not alter the clinical course if started late, with erythromycin being effective in eliminating the organism from the nasopharynx 9

Pertussis Diagnosis and Examination Findings

Classic Physical Examination Findings

• The physical examination in pertussis is often surprisingly unremarkable between coughing episodes, with the diagnosis primarily relying on observing or eliciting the characteristic paroxysmal cough pattern rather than specific physical signs, as noted by the American Thoracic Society 10
• Paroxysmal coughing is the hallmark finding—a series of rapid expiratory bursts followed by a sudden loud inspiratory sound (the "whoop"), though this classic whoop is frequently absent in adults and previously vaccinated individuals, according to the American Academy of Pediatrics 10
• Normal lung auscultation between paroxysms is common, as pertussis primarily affects the airways rather than causing parenchymal disease, as stated by the American College of Chest Physicians 10

Age-Specific Examination Variations

• Prolonged paroxysmal cough lasting 4-6 weeks without other specific findings is common in adolescents and adults, as reported by the Centers for Disease Control and Prevention 10
• Shortness of breath and tingling sensation in the throat may be reported by patients with pertussis, as noted by the World Health Organization 10
• Physical signs of chronic cough complications including petechiae, subconjunctival hemorrhages, or rib tenderness from cough-related trauma may be observed in patients with pertussis, as stated by the European Respiratory Society 10

Laboratory Findings

• Leukocytosis with lymphocytosis, classically described in pertussis, is frequently absent and should not be relied upon for diagnosis, as reported by the Infectious Diseases Society of America 10

Clinical Case Definition for Diagnosis

• Cough persisting >2 weeks accompanied by any of the following: paroxysms of coughing, post-tussive vomiting, or inspiratory whooping sound is a clinical case definition for diagnosis, as defined by the World Health Organization 11 and the Centers for Disease Control and Prevention 12

Pertussis Diagnosis and Treatment

Diagnosis

• When a patient has cough lasting ≥2 weeks accompanied by paroxysms of coughing, post-tussive vomiting, and/or inspiratory whooping sound, diagnose pertussis unless another diagnosis is proven, as recommended by the American College of Chest Physicians 13, 14, 15
• Confirmed diagnosis requires either positive culture or compatible clinical picture with epidemiologic linkage to a confirmed case, according to the American College of Chest Physicians 13, 14, 15
• Culture is 100% specific but isolation of bacteria is the only certain way to make the diagnosis, as stated by the American College of Chest Physicians 13, 14, 15
• Serology, such as paired acute and convalescent sera showing fourfold increase in IgG or IgA antibodies to PT or FHA, can be used for diagnosis with 72%-100% specificity, as recommended by the American College of Chest Physicians 13, 14, 15

Treatment

• All children and adults with confirmed or probable whooping cough should receive a macrolide antibiotic, preferably azithromycin, and be isolated for 5 days from the start of treatment, as recommended by the American College of Chest Physicians 13, 14, 15
• Early treatment within the first few weeks diminishes coughing paroxysms and prevents disease spread, according to the American College of Chest Physicians 13, 14, 15
• Treatment beyond 3 weeks after cough onset may be offered but the patient is unlikely to respond, as stated by the American College of Chest Physicians 13, 14, 15
• Isolate patients for 5 days from the start of antibiotic treatment, as recommended by the American College of Chest Physicians 13, 14, 15

Prevention

• All children should receive complete DTaP primary vaccination series followed by a single dose DTaP booster early in adolescence, as recommended by the American College of Chest Physicians 13, 14, 15
• For all adults up to age 65, administer TDap vaccine according to CDC guidelines, as recommended by the American College of Chest Physicians 13, 14, 15

Pertussis (Whooping Cough) – Diagnosis, Treatment, and Immunization Guidelines

Clinical Diagnosis

• Diagnostic criteria: Cough lasting ≥ 2 weeks with paroxysms, post‑tussive vomiting, and/or an inspiratory “whoop” should be considered pertussis unless another cause is identified. (American College of Chest Physicians) 16, 17
• Catarrhal stage (≈ 1‑2 weeks): Nonspecific upper‑respiratory symptoms (nasal congestion, rhinorrhea, mild sore throat, dry cough, minimal or no fever) that mimic common viral infections. (CDC) 18
• Paroxysmal stage (≈ 4‑6 weeks): Severe coughing bursts often followed by an inspiratory “whoop” and post‑tussive vomiting. (CDC) 18
• Convalescent stage (≥ 2 weeks, may last months): Gradual reduction in cough frequency; a non‑paroxysmal cough can persist for months. (CDC) 18
• Infants: May present atypically with apneic spells and little or no cough rather than classic whooping. (CDC) 18

Laboratory Confirmation

• Culture: Provides 100 % specificity and enables antimicrobial susceptibility testing and molecular subtyping; results require 1‑2 weeks. (American College of Chest Physicians) 16
• Confirmed case definition: Positive culture or PCR positivity with compatible clinical picture or a clinically defined case with epidemiologic linkage to a laboratory‑confirmed case. (American College of Chest Physicians) 16, 19
• Serology: A paired acute‑ and convalescent‑phase serum showing a ≥ four‑fold rise in IgG or IgA antibodies to pertussis toxin or filamentous hemagglutinin offers a presumptive diagnosis. (American College of Chest Physicians) 16, 17

Treatment

• General recommendation: All patients (children and adults) with confirmed or probable pertussis should receive a macrolide antibiotic and be isolated for 5 days from the start of therapy. (American College of Chest Physicians) 16, 17, 19

First‑Line Antibiotic Regimen

(CDC) 18

Alternative Regimens

• Erythromycin: 1 g/day for adults or 40‑50 mg/kg/day for children for 14 days. (CDC) 18
• Clarithromycin: 500 mg twice daily for adults or 15‑20 mg/kg/day in two divided doses for children for 10‑14 days. (CDC) 18
• Macrolide allergy/intolerance: Trimethoprim‑sulfamethoxazole 320 mg/1600 mg daily for adults or 8 mg/40 mg/kg/day for children for 14 days. (CDC) 18

Timing and Efficacy

• Initiating therapy within the first 2‑3 weeks of cough reduces paroxysmal coughing and limits transmission. (American College of Chest Physicians) 16, 17, 19
• Treatment started after > 3 weeks of cough is unlikely to produce clinical improvement. (American College of Chest Physicians) 16, 17, 19

Isolation

• Patients should remain isolated for 5 days from the commencement of antibiotic therapy. (American College of Chest Physicians) 16, 17, 19
• Infectivity peaks during the catarrhal stage and the first 3 weeks after cough onset. (CDC) 18

Ineffective Adjunctive Therapies

• Long‑acting β‑agonists, antihistamines, systemic corticosteroids, and pertussis‑specific immunoglobulin have no demonstrated benefit in pertussis management. (American College of Chest Physicians) 16, 17, 19

Immunization

• Childhood schedule: Complete the 5‑dose DTaP series at ages 2 months, 4 months, 6 months, 15‑18 months, and 4‑6 years; administer a single Tdap booster between ages 11‑18 years. (American College of Chest Physicians & CDC) 16, 17, 18, 19
• Adolescents (11‑18 years): One dose of Tdap. (CDC) 18
• Adults (19‑64 years): One dose of Tdap if not previously received. (American College of Chest Physicians & CDC) 16, 18, 19
• Immunity durability: Protective immunity wanes 5‑10 years after the last pertussis vaccine dose. (CDC) 18
• Coverage target: Population vaccination coverage should exceed 90 % to curb transmission; the secondary attack rate among susceptible contacts exceeds 80 %. (CDC) 18

All facts are derived from cited guideline sources and presented with the strength of evidence as reported in the original references.